Jeffrey E. Lancet, MD

BOARD CERTIFICATION:
          •  Hematology

FELLOWSHIP:
          •  Rochester School of Medicine & Dentistry - Hematology/Oncology

RESIDENCY:
          •  St. Mary's Hospital, Rochester School of Medicine & Dentistry
          •  Strong Memorial Hospital, Rochester School of Medicine & Dentistry

MEDICAL SCHOOL:
          •  SUNY Upstate Medical College - MD

• Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May;37(5):510-515. Pubmedid: 23332452.


• Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Apr. Pubmedid: 23632888.


• Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr. Pubmedid: 23605934.


• Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.


• Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013 Mar;37(3):300-304. Pubmedid: 23273539.


• Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol. 2013 Mar;20(2):100-106. Pubmedid: 23385612.


• Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, Jurcic JG. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013 Jan;98(1):119-128. Pubmedid: 22801961.


• Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec;120(25):4945-4951. Pubmedid: 22915641. Pmcid: PMC3525020.


• Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.


• Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct;120(17):3419-3424. Pubmedid: 22936658.


• O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM. Acute myeloid leukemia. J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021. Pubmedid: 22878824.


• Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.


• Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan;36(1):72-80. Pubmedid: 21782240.


• Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 2011 Dec;25(12):1808-1814. Pubmedid: 21760592.


• Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl. 2011 Aug;5(7-8):383-396. Pubmedid: 21656910. Pmcid: PMC3530891.


• Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Mel?ndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug;52(8):1528-1536. Pubmedid: 21635204.


• Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011 Jul;118(3):523-528. Pubmedid: 21551228. Pmcid: PMC3142897.


• Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.


• Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr;117(7):1463-1469. Pubmedid: 21425147.


• Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011 Mar;29(8):979-985. Pubmedid: 21282541.


• Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Mar;17(3):384-393. Pubmedid: 20655389.


• Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.


• Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar;17(5):1140-1146. Pubmedid: 21233404. Pmcid: PMC3049960.


• Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP, Stiff PJ, Appelbaum FR. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010 Dec;151(5):430-434. Pubmedid: 21113977. Pmcid: PMC3058291.


• Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2010 Nov. Pubmedid: 21061347.


• Lancet J, Feldman E, Kolitz J, Tallman M, Hogge DE, Louie A. Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):E28-. Pubmedid: 20511145.


• Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr;24(4):699-705. Pubmedid: 20111068.


• Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.


• Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?. Curr Hematol Malig Rep. 2010 Jan;5(1):9-14. Pubmedid: 20425391.


• Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res. 2009 Aug;33(8):1055-1061. Pubmedid: 19108889.


• Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. Leuk Res. 2009 Jun;33(6):769-774. Pubmedid: 18976810.


• Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 2009 Jun;113(26):6533-6540. Pubmedid: 19398716.


• Lancet JE, Karp JE. Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol. 2009 Mar;16(2):105-111. Pubmedid: 19468272. Pmcid: PMC2861990.


• Lancet JE, Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw. 2008 Nov;6(10):1017-1025. Pubmedid: 19176199.


• Karp JE, Lancet JE. Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500. Pubmedid: 19707379.


• Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May;14(10):3077-3082. Pubmedid: 18483374. Pmcid: PMC3074480.


• Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I, Feldman EJ, Gotlib J, Morris LE, Greenberg PL, Wright JJ, Harousseau JL, L?wenberg B, Stone RM, De Porre P, Wang Y, Karp JE. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar;111(5):2589-2596. Pubmedid: 18160667.


• Karp J, Lancet J. Development of farnesyltransferase inhibitors for clinical cancer therapy: focuson hematologic malignancies. Cancer Invest. 2007 Sep;25(6):484-494. Pubmedid: 17882662.


• Harousseau J, Lancet J, Reiffers J, Lowenberg B, Thomas X, Huguet F, Fenaux P, Zhang S, Rackoff W, De Porre P, Stone R. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007 Jun;109(12):5151-6. Pubmedid: 17351110.


• Raponi M, Harousseau J, Lancet J, Lowenberg B, Stone R, Zhang Y, RackoffW, Wang Y, Atkins D. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2007 Apr;13(7):2254-2260. Pubmedid: 17404110.


• Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia. 2007 Mar;21(3):586-588. Pubmedid: 17230228.


• Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb;109(4):1387-94. Pubmedid: 17082323.


• O'Donnell M, Appelbaum F, Baer M, Byrd J, Coutre S, Damon L, Erba H, Estey E, Foran J, Lancet J, Maness L, Maslak P, Millenson M, Moore J, Przepiorka D, Shami P, Smith B, Stone R, Tallman M. Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jan;4(1):16-36. Pubmedid: 16403402.


• Liesveld JL, Rosell KE, Lu C, Bechelli J, Phillips G, Lancet JE, Abboud CN. Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology. 2005 Dec;10(6):483-494. Pubmedid: 16321813.


• Karp J, Lancet J. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. Fut Oncol. 2005 Dec;1(6):719-731. Pubmedid: 16556050.


• Karp J, Lancet J. Targeting the process of farynesylation for therapy of hematologic malignancies. Curr Mol Med. 2005 Nov;5(7):643-652. Pubmedid: 16305490.


• Lancet J, Karp J. Farnesyl transferase inhibitors in myeloid disorders. Oncology (Williston Park). 2005 Jul;19(8):1043-1049. Pubmedid: 16131046.


• Raponi M, Belly RT, Karp JE, Lancet JE, Atkins D, Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. Bmc Cancer. 2004 Aug;4:56-56. Pubmedid: 15329151.


• O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul;28(7):679-689. Pubmedid: 15158089.


• Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res. 2004 Jan;10(1 Pt 1):88-95. Pubmedid: 14734456.


• Liesveld JL, Lancet JE, Rosell KE, Menon A, Lu C, McNair C, Abboud CN, Rosenblatt JD. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia. 2003 Sep;17(9):1806-1812. Pubmedid: 12970780.


• Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev. 2003 Sep;17(3):123-129. Pubmedid: 12818222.


• Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, VerstovsekS, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug;102(3):795-801. Pubmedid: 12649163.


• Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr;97(8):1920-1928. Pubmedid: 12673719.


• Rathnasabapathy R, Lancet J. Management of acute myelogenous leukemia in the elderly. Cancer Control. 2003;10(6):469-477. Pubmedid: 14652523.


• Komrokji R, Lancet J, Felgar R, Wang N, Bennett J. Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature. Leuk Res. 2003;27(6):561-566. Pubmedid: 12648517.


• Lancet J, Karp J. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood. 2003;102(12):3880-3889. Pubmedid: 12920034.


• Lancet J, Rosenblatt J, Karp J. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin Hematol. 2002;39(3):31-35. Pubmedid: 12214291.


• Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. Biol Blood Marrow Transplant. 2002;8(12):662-665. Pubmedid: 12523578.


• Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012 Oct;36(10):1283-1289. Pubmedid: 22840315.


• Naghashpour M, Lancet J, Moscinski L, Zhang L. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report. Am J Hematol. 2010 Jun;85(6):451-454. Pubmedid: 20513125.

Direct care of patients with acute and chronic leukemias, as well as myelodysplastic syndromes.